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NEMO (NF-B essential modulator) is a regulatory protein
essential to the canonical NF-B signaling pathway, notably
involved in immune and inflammatory responses, apoptosis,
and oncogenesis. Here, we report that the zinc finger (ZF)motif,
located in the regulatory C-terminal half of NEMO, forms a spe-
cific complex with ubiquitin. We have investigated the NEMO
ZF-ubiquitin interaction and proposed a structuralmodel of the
complex based on NMR, fluorescence, and mutagenesis data
andon the sequencehomologywith thepolymeraseubiquitin-
binding zinc finger involved in DNA repair. Functional comple-
mentation assays and in vivo pull-down experiments further
show that ZF residues involved in ubiquitin binding are func-
tionally important and required forNF-B signaling in response
to tumor necrosis factor-. Thus, our findings indicate that
NEMO ZF is a bona fide ubiquitin-binding domain of the ubiq-
uitin-binding zinc finger type.
The NF-B transcription factors regulate the expression of
genes involved in inflammation, immunity, cell proliferation,
apoptosis, and oncogenesis (1). The classical NF-B signaling
pathway is induced in response to proinflammatory cytokines
(interleukin-1, TNF-),5 antigens, and endotoxins. Although
different receptors and downstream molecules are engaged
depending on the stimulus, they all transduce signals through
the IKK complex. These active complexes comprise two cata-
lytic kinase subunits, IKK and/or IKK, and a dimer of regu-
latory subunits termed NEMO, which is required for IKK com-
plex activity and subsequent NF-B activation (2, 3).
The N-terminal part of NEMO interacts with the IKK
kinases, whereas the regulatory C-terminal half is involved in
signal recognition (4, 5). The latter comprises the CC2-LZ
domain, including a coiled-coil (CC2) and a leucine zipper (LZ)
motif and a CCHC-type zinc finger (ZF) domain (Fig. 1). The
CC2-LZ domain is required for NEMO oligomerization (6, 7)
and contains a ubiquitin-binding domain (UBD) that preferen-
tially interacts with Lys-63-polyubiquitin (Lys-63-polyUb)
chains (8, 9). Lys-63-polyUb binding through the CC2-LZ
domain of NEMO is required for NF-B signaling from several
different receptors. In the case of TNF- receptor 1 (TNFR1),
the IKK complex seems to be recruited to the TNFR1 receptor
via interaction with Lys-63-polyubiquitinated RIP1 protein (8,
9). In addition to binding Lys-63-polyUb, a minor fraction of
NEMOundergoes ubiquitination (post-translational modifica-
tion via the covalent attachment of ubiquitin) within the regu-
latory portion of NEMO. Several monoubiquitination and Lys-
63-polyubiquitination sites on NEMO have been identified,
including a Lys-399 residue in the ZF domain (10), and the site
of modification and its impact on IKK activity appear to be
signal-dependent (11–13).
Although the CC2-LZ domain of NEMO is required for a
wide range of NF-B-inducing signals, the role of the NEMO
ZF domain remains controversial (14, 15) and appears to
depend on the stimulus. Several studies reported that NEMO
ZF is required for interleukin-1 andTNF- but not lipopolysac-
charide-induced signaling (16, 17). On the other hand, a clear
requirement for ZF in the genotoxic stress response has been
established (12, 18). This distinct pathway is activated by UV
radiation and otherDNA-damaging agents and involves import
of NEMO into the nucleus, where it interacts with the ataxia
telangiectasia mutated (ATM) checkpoint kinase. The impor-
tance ofNEMOZF is also emphasized by the fact that (i) several
mutations in the ZF are linked to the human diseases, anhi-
drotic ectodermal dysplasiawith immunodeficiency and incon-
tinentia pigmenti (19), and that (ii) mice lacking the NEMOZF
die during embryonic development (20).
We recently determined the solution structure of NEMOZF
(21), which highlighted the importance of a large hydrophobic
cluster sharing similarities with the ubiquitin-interacting
region of the ubiquitin-binding ZF (UBZ) of the human DNA
Y-polymerase (pol)  (22). Because UBDs are usually found in
multiple copies in proteins, the question arises whether NEMO
ZF could actually act as a second ubiquitin-binding site, in addi-
tion to the CC2-LZ domain. We show here, using NMR, fluo-
rescence,mutagenesis, and in vivo pull-down experiments, that
NEMO ZF is a bona fideUBD of the UBZ type. We have inves-
tigated the ZF-ubiquitin interaction, proposed a model of the
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complex, and further showed that ZF residues involved in ubiq-
uitin binding are functionally important and required for
NF-B signaling in response to TNF-.
EXPERIMENTAL PROCEDURES
Sample Preparation—NEMO ZF synthetic peptides (98%
purity) termini-blocked by N-acetyl and C-amide groups were
purchased from Biopeptide Co. (San Diego, CA). Five different
peptides were used in this study; ZF corresponds to 2 Ser resi-
dues followed by residues 394–419 of human NEMO. In
ZF(W), Phe-395 is replaced by a tryptophan. ZF(W)-M407V,
ZF(W)-V414S, and ZF(W)-M415S are three point mutant pep-
tides of ZF(W). The sequences are given in supplemental Fig.
S1. For binding assays, each of the four ZF(W) peptides was
solubilized in a buffer of 0.6mMZnCl2, 1mM tris(2-carboxyeth-
yl)phosphine, and 50 mM Tris-HCl (pH 7.5) to a stock concen-
tration of 0.2 mM. Recombinant human ubiquitin and the
I44A ubiquitin mutant were purchased from Boston Biochem
at 95% purity. Ubiquitin was further purified by cation
exchange column, dialyzed in water, lyophilized, and solubi-
lized in 50 mM Tris-HCl (pH 7.5). For NMR, 1.7 mM of the ZF
was prepared by dissolving 2.8mgof peptide in 500l of 3.4mM
ZnCl2, 3.4mM tris(2-carboxyethyl)phosphine, 20mMTris-HCl,
90% H2O, 10% D2O (pH 6.2). The U-15N-labeled human ubiq-
uitin was purchased fromVLI Research Inc. (Malvern, PA), and
a 1mM stock solutionwas prepared in exactly the same buffer as
theZF. ThreeNMRsamples of ZF-ubiquitin complexwere suc-
cessively prepared at concentrations (ratio) of 1.45:0.15 mM
(r 9.7), 0.87:0.15 mM (r 5.8), and 0.24:0.15 mM (r 1.6).
NMR Spectroscopy—NMR experiments were carried out at
25 °C on a Varian Inova 600-MHz spectrometer equipped with
a cryoprobe. 1H-15N heteronuclear single quantum correlation
spectra were recorded with 200 (90 ms) and 1024 (122 ms)
complex points (acquisition times) in 15N and 1H, respectively.
Average (1H, 15N) chemical shift changes upon binding were
calculated asav [(H)2 (N/5)2]1⁄2. The binding affinity
(KD) was estimated by fitting the ZF titration data, assuming a
simple complex formation model and using nonlinear regres-
sion. 15N relaxation data (T1, T2, and {1H}-15N NOE) were
acquired by standard methods (23).
Docking—The docking was performed with HADDOCK 1.3
(24), with initial coordinates of NEMO ZF and ubiquitin taken
from their structure in free form (Protein Data Bank entries
2JVX and 1D3Z, respectively) and by using 16 ambiguous inter-
action restraints. The latter were defined on the basis of the
NMR chemical shift mapping, surface accessibility data, and
the homology with the pol  UBZ signature motif.
Binding Affinity—Tryptophan fluorescence measurements
were recorded on a PTI QuantaMaster spectrofluorimeter
(PTI, Lawrenceville, NJ) at 22 °C. The excitation wavelength
was set to 295 nm to minimize the contribution of the tyrosyl
group. The fluorescence emission at 352 nm was measured
using 20 M peptide and 20–500 M ubiquitin. The observed
fluorescence (Fobs) was corrected for dilution and for fluores-
cence from ubiquitin alone. Data for the ZF(W) peptide were
fitted by nonlinear regression using the equation (Fobs F0)
(Fmax F0) [L]/(KD [L]) to solve the maximum fluorescence
(Fmax) and the dissociation constant (KD), given [L] (ligand con-
centration), F0 (fluorescence in the absence of ligand), and Fobs.
The KD for ZF(W) mutant peptides was estimated using the
Fmax value obtained for ZF(W). For ZF peptide folding experi-
ments, ZF peptide stocks, prepared in the presence or absence
of ZnCl2, were diluted to 20 M in 50 mM Tris-HCl (pH 7.5).
The emission spectra (305–415 nm) for these peptides were
recorded, the buffer contribution was subtracted, and the fluo-
rescence quantum yields were determined usingN-acetyl tryp-
tophanamide (Sigma) as standard as described previously (25).
Plasmid Construction—A pcDNA3 vector encoding FLAG-
tagged human NEMO protein (residues 2–419) was used to
generate five NEMO mutant constructs, including point
mutants M407V, Q411R, V414S, and M415S and a NEMO ZF
deletion (ZF). Substitutions were chosen conservatively, so as
not to perturb the overall structure of the ZF domain. The point
mutations were generated using overlap PCR. The primer
sequences used for PCR are available upon request. The final
PCRproductwas digestedwith EcoRI andXhoI and ligated into
the pcDNA3-FLAG vector. A NEMO construct lacking 25
C-terminal residues (ZF) was generated using PCR introduc-
ing a stop codon after residue 394. The PCR product was
digested and cloned as described above.
Functional Complementation Experiments—4  106
NEMO/ Jurkat T cells (JM4.5.2) (26) were transfected with 3
g of pcDNA3-FLAG (empty or with various NEMO con-
structs), 1 g of Ig-luciferase, and 300 ng of -galactosidase
plasmids using DEAE-dextran as described previously (27).
After 24 h, cells were treated with TNF- (10 ng/ml) for 4 h and
then harvested. Luciferase activity in soluble cell extracts was
measured as described (27). -galactosidase activity was meas-
ured using the luminescent-galactosidase detection kit (Clon-
tech) according to manufacturer’s instructions. The level of
luciferase, representing NF-B activity, was normalized to the
level of -galactosidase, representing transfection efficiency.
Immunoprecipitation and Western Blot Analysis—293T
cells, grown in 6-well dishes, were transfectedwith 8l of Lipo-
fectamine 2000 (Invitrogen) and 3g of pcDNA-FLAGplasmid
(empty or with various NEMO constructs) and harvested 24 h
after transfection. Cells were lysed in 25 mM Tris-phosphate
(pH 7.8), 1mMdithioerythritol, 1%TritonX-100, and 10% glyc-
erol (for Western blot analysis) or in 50 mM Tris-HCl (pH 7.4),
150mMNaCl, and 1%TritonX-100 (for immunoprecipitation).
FLAG-NEMO was immunoprecipitated using the FLAG
immunoprecipitation kit (Sigma) according to themanufactur-
er’s protocol. FLAG-NEMO proteins were detected using anti-
FLAG M2 (Sigma) or anti-NEMO (antibody B24, homemade)
FIGURE 1. Structural and functional domains of the NEMO protein. Struc-
tural domains include the coiled-coil (CC1 and CC2), LZ, and ZF motifs. The
functional NEMO domains are indicated on the top. Sequence numbering is
given for the human NEMO protein.
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antibodies, and ubiquitin was detected using anti-ubiquitin
(antibody 6C1, Sigma) antibody.
RESULTS ANDDISCUSSION
NEMO ZF Binds Ubiquitin—The binding of a NEMO ZF
synthetic peptide (see the sequence in supplemental Fig. S1) to
ubiquitin was probed by NMR chemical shift perturbation
experiments. The 1H and 15N chemical shifts of several ubiq-
uitin residues vary gradually from the free (Fig. 2A, black) to the
bound state (red) upon the addition of ZF, as typically observed
for a complex in fast exchange on the NMR time scale. Signifi-
cant average chemical shift changes (av) or attenuations of
peak intensities are observed for a number of residues (Fig. 2B),
thus identifying the binding surface on ubiquitin. Most of these
residues are spatially located around Leu-8, Ile-44, and Val-70,
i.e. on the conserved hydrophobic region of the five-stranded
-sheet of ubiquitin typically recognized by UBDs (28) (see Fig.
4C). Backbone dynamics from 15N relaxation measurements
(T1, T2, and {1H}-15N NOE) were evaluated for the free and
ZF-bound state of ubiquitin (Fig. 2C). Isotropic rotational cor-
relation times, estimated from the T1/T2 ratios of nonflexible
residues, are 4.3 and 6.3 ns for the free and bound ubiquitin,
respectively. Despite the small difference, these values are in
good agreement with theoretical values of 4.1 and 5.7 ns
expected for globular molecules with respective molecular
masses of 8.5 and 11.8 kDa, suggesting the formation of a 1:1
complex. Overall, the internal mobility of ubiquitin is not sig-
nificantly affected by peptide binding, with rather uniform and
unchangedT1, T2, and {1H}-15NNOEprofiles. This denotes the
formation of a stable complex, although slightly more confor-
mational exchange can be detected on the microsecond to mil-
lisecond time scale, especially for residues Phe-4, Thr-7, Ile-13,
Thr-14, Gln-41, Arg-42, Lys-48, Gln-49, His-68, Val-70, Leu-
71, and Arg-72 in the five-stranded -sheet, as seen from their
relatively lower T2 values in the bound state.
The binding affinity (KD) of the ZF-ubiquitin complex was
estimated to be280 90 M by NMR. Because we observed
the presence of peptide aggregates at high ZF concentration
(21), we confirmed this affinity by tryptophan fluorescence
spectroscopy, using a synthetic peptide containing the F395W
substitution, denoted as ZF(W) (see the sequence in supple-
mental Fig. S1). This substitution does not affect the ability of
ZF(W) to properly fold upon the addition of zinc (Fig. 3B). As
seen in Fig. 3A, an increase in fluorescence signal is observed
during ubiquitin titration (filled circles), corresponding to a KD
of 253  15 M, which is within the range reported for other
UBDs (10–500 M) (28). Note that the KD value from fluores-
cence data is in agreement with the one estimated by NMR,
indicating that the F395W substitution does not markedly
affect the interaction. Ubiquitin containing the I44A mutation
does not bind ZF(W) (filled triangle), showing that the increase
in fluorescence is due to the formation of a specific NEMO
ZF-ubiquitin complex and that residue Ile-44 is crucial for
binding to NEMO ZF.
Structural Model of the NEMO ZF-Ubiquitin Complex—In
the  structure of NEMO ZF, a large hydrophobic cluster
encompassing the hydrophobic side of the -helix was antici-
pated to be a potential protein-binding surface (21). As seen on
FIGURE 2.NMRchemical shift perturbations of ubiquitin uponbinding to
NEMO ZF. A, regions of 1H-15N heteronuclear single quantum correlation
spectra obtained from the titration of 0.15 mM 15N-labeled ubiquitin with
increasing amounts of unlabeled ZF peptide (pH 6.2, 25 °C). ZF to ubiquitin
ratios (r)were0 (freeubiquitin,black), 1.6 (yellow), 5.8 (orange), and9.7 (bound
ubiquitin, red). B, weighted average chemical shift changes av versus ubiq-
uitin residue number for each r 0 as defined in A, relative to r 0. Values of
av are shown for the Asn and Gln side chain NH2 groups (red diamonds) for
r 9.7. The green asterisks denote residues for which the relative peak inten-
sities in bound ubiquitin are attenuated as compared with free ubiquitin.
C, backbonedynamics of ubiquitin in its free form (black) and in complexwith
NEMO ZF (red, ZF-ubiquitin ratio of 9.7) from 15N relaxation data. 15N longitu-
dinal (T1) and transversal (T2) relaxation times and {
1H}-15N NOE values are
plotted in the top, middle, and bottom panel, respectively. Secondary struc-
ture elements are indicated at the top.
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Fig. 4A, this region shares similarities with other ubiquitin-
binding helices, notably with that of the pol UBZ domain (22)
and, to a lesser extent, with the inverted ubiquitin-interacting
motif (UIM) of Rabex-5 (29, 30). Key residues at positions7,
4, 3, 1, and 3 that are important for binding are con-
served in NEMO ZF, whereas the central invariant Ala (posi-
tion 0) is replaced by a Met. The binding interfaces on NEMO
ZF (Fig. 4B) and on ubiquitin (Fig. 4C) were therefore defined
according to the sequence homologywith theUBZmotif and to
the NMR chemical shift perturbation data, respectively.
On the basis of these two interfaces, we determined a docking
model of the ZF-ubiquitin complex (Fig. 4D), using the HAD-
DOCK program (24). We found that the hydrophobic side of
the ZF -helix interacts with the typically recognized hydro-
phobic region around Ile-44 of ubiquitin in a similar manner as
the UBZ -helix (see Fig. 3D of Ref. 22). Differences are, how-
ever, evident in the overall binding mode of the zinc fingers.
Notably, the 4-residue shift observed from the relative position
of the last 2 zinc-chelating residues in the sequence alignment
translates into a shift of the NEMOhelix bymore than one turn
into the ubiquitin C terminus direction and leads to a slightly
different orientation of the finger with respect to ubiquitin.
These differences are in agreement with the fact that the -he-
lix in NEMO ZF is shorter than in the pol  UBZ by about one
helical turn. The interaction between ubiquitin and NEMO ZF
leads to a buried surface area of 1014  55 Å2 and is largely
driven by hydrophobic forces, involving all or part of the side
chains of Gln-411, Ile-412, Val-414,Met-415, and Ile-418 of the
ZF and notably the ubiquitin residues Leu-8, Ile-44, andVal-70.
In the pol UBZ, the mutation of the central invariant Ala into
a Phe was shown to abolish binding. However, in NEMO ZF,
the residueMet-415 at the equivalent position inserts perfectly
into the hydrophobic cleft formed by Leu-8, Ile-44, His-68, and
Val-70, suggesting local differences between the pol UBZ and
theNEMOZFaround this position. In addition to these numer-
ous hydrophobic contacts, the side chains of Asp-408 and Gln-
411 at positions 7 and 4, respectively, likely contribute to
the binding by allowing the formation of hydrogen bonds with
the backbone amide or carbonyl groups of the loop residues
Ala-46 to Lys-48 of ubiquitin, in a similar way as the corre-
sponding Glu and Asp residues in the pol  UBZ.
To validate our model of the NEMO ZF-ubiquitin complex,
we examined the ability of three modified ZF(W) peptides to
interact with ubiquitin using fluorescence. In addition to the
F395W substitution, these ZF(W) peptides contain the point
mutationM407V (identified in a patient with the incontinentia
pigmenti pathology (31)), V414S, or M415S. The ZF(W)-
M407V and ZF(W)-M415S peptides show an4-fold decrease
in binding affinity, and ZF(W)-V414S displays the greatest
defect, with a complete loss in ubiquitin binding (Fig. 3A). Note
that the fluorescence quantum yields in the presence of zinc are
similar for all peptides, indicating that the reduced binding
affinity of these peptides is not due to a global perturbation of
the NEMOZF fold (Fig. 3B and supplemental Table S1). These
mutagenesis results are fully consistent with our model, attest-
ing that residues Val-414 andMet-415, which lay on the central
hydrophobic part of the interface, are crucial for ubiquitin
binding. Furthermore, the reduced binding affinity observed
for the pathogenicM407Vmutant likely results from the loss of
peripheral hydrophobic contacts between the long Met-407
side chain and Lys-48 (Fig. 4D).
Biological Relevance of the NEMO ZF-Ubiquitin Interaction
in Vivo—Next, we addressed the question whether the interac-
tion between NEMO ZF and ubiquitin is important for NF-B
activation. Using the full-length protein, we investigated
whether ZFmutations located at the binding interface (M407V,
Q411R, V414S, and M415S) are able to restore NF-B activa-
tion in NEMO-deficient T-lymphocytes using an NF-B-in-
ducible luciferase reporter assay. Transfection of NEMO-ex-
pressing plasmids does not lead to a significant increase in
luciferase activity in the absence of TNF- (data not shown).
On the other hand, stimulation with TNF- leads to a 60-fold
increase in activity inNEMOWT-expressing cells (set at 100%)
as compared with empty plasmid (mock) control (Fig. 5A). All
NEMO mutant constructs display a defect in NF-B signaling
to varying extents,M407Vbeing the least severe (50%activity as
compared with WT). Most notably, NEMO point mutations
FIGURE 3. Ubiquitin binding affinities and folding of NEMO ZF peptides
assayed by tryptophan fluorescence. A, the change of fluorescence emis-
sion (Fobs F0) upon ubiquitin titration is shown for ZF(W) and three ZF(W)
mutants (see inset). Titrations were performed with 20M peptide. Error bars
represent standard deviations from two independent experiments. The dis-
sociation constants (KD) are given in the inset. No bindingwas observed in the
presence of ZF(W) peptide and the ubiquitin I44Amutant (UbI44A, filled trian-
gle). a.u., absorbance units. B, ZF(W) mutant peptides fold similarly upon the
addition of zinc. The emission spectra (305–415 nm), subtracted from buffer
alone, were obtained upon tryptophan excitation at 295 nm. ZF(W) peptides at
20 M were assayed in the absence (Zn) or presence (Zn) of zinc. The
addition of zinc leads to a similar increase in fluorescence for all ZF(W) pep-
tides, indicating that the mutations do not disrupt global zinc finger folding.
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V414S and M415S are just as inefficient in activating NF-B as
the ZF construct (5% residual activity). The inability to
stimulate NF-B signaling in these cells is not due to altered
NEMO protein expression or solubility because all NEMO
proteins are detected at similar
levels upon transfection (Fig. 5B).
Therefore, mutations of ZF resi-
dues that exhibit a defect in ubiq-
uitin binding impair TNF--in-
duced NF-B signaling in T
lymphocytes, highlighting the
importance of ubiquitin recognition
by the ZF motif, mostly via crucial
hydrophobic contacts.
We finally examined whether the
M415S mutation, which shows the
most severe defect in NF-B signal-
ing, affects the ability of NEMO to
bind ubiquitinated proteins in vivo.
Pull-down of FLAG-tagged NEMO
WTprotein after transient transfec-
tion in 293T cells leads to co-elution
of a pattern of ubiquitinated pro-
teins, whereas less ubiquitinated
proteins co-elute with NEMO
M415S (Fig. 5C). Hence, such a
mutation in the ubiquitin-binding
surface of the ZF reduces the ability
of NEMO to bind ubiquitinated
proteins, indicating that NEMO ZF
is involved in ubiquitin binding in
vivo.
Altogether, our results clearly
reveal the role of the ZF as a novel
ubiquitin-binding domain in NEMO, namely of the UBZ type,
thereby providing new insights into the mechanism of ubiq-
uitin recognition byNEMOto activate theNF-Bpathway. The
moderate ZF affinity for ubiquitin, allowing transient complex
formation, might be increased in the context of the full-length
protein, which contains another UBD in the CC2-LZ domain.
We propose that the ZF acts in a cooperative manner with the
CC2-LZ domain to strengthen ubiquitin recognition and to
preferentially bind polyubiquitin chains rather thanmonoubiq-
uitin. Finally, our results suggest that, like other ectodermal
dysplasia with immunodeficiency and incontinentia pigmenti
mutations located in the CC2-LZUBD, pathological mutations
in NEMO ZF likely impair NF-B activation by disrupting the
binding to ubiquitin.
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FIGURE 5. In vivo analysis ofmutations in the NEMOZFUBD. A, mutations
in NEMO ZF result in a defect in TNF--induced NF-B activation. NEMO-
deficient Jurkat cells were co-transfected with an NF-B-inducible luciferase
reporter plasmid andanemptyplasmid (mock) or a plasmid expressing FLAG-
tagged NEMO: WT, point mutants M407V, Q411R, V414S, or M415S, or ZF-
deleted (ZF). Cells were stimulated with TNF-, and luciferase activity was
measured after 4 h. Data represent two independent experiments performed
in duplicate. B, NEMO WT and mutant constructs are expressed at similar
levels. FLAG-NEMOproteinswere detected upon transfection in 293T cells by
immunoblot using anti-FLAG antibody (nucleoside diphosphate kinase
(NDPK) is shown as an internal control). C, a mutation in NEMO ZF leads to a
defect in ubiquitin binding in vivo. Lysates from 293T cells transfected with
mock plasmid or plasmid encoding FLAG-NEMOWTorM415Swere immuno-
precipitated (IP) with anti-FLAG antibody. Immunoprecipitates were ana-
lyzed by immunoblot (IB) using anti-ubiquitin (-Ub, top panel) or anti-NEMO
(-NEMO, bottom panel) antibody.
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